Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

Hospices Civils de Lyon100 enrolled

Overview

The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Bone and Joint Infection Staphylococcus Aureus

Interventions

Delta-haemolysinOTHER

comparison of groups having infection with S. aureus with and without delta-haemolysin Production

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients having implant infection due to S. aureus treated by DAIR Exclusion Criteria: * none

Locations (1)

Hospices Civils de Lyon

Lyon, France

RECRUITING

Outcomes

Primary Outcomes

Rate of infection with or witout delta-haemolysin in Staphylococcus Aureus

patients, profile of the bacterium, medical and chirurgical treatment, rate. comparison between the 2 groups

Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Secondary Outcomes

Rate of Treatment Failure

Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. Comparison between the 2 groups

Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption

Central Contacts

Johanna Boulant, CRA

CONTACT

johanna.boulant@chu-lyon.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.